



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DKT NO. T103 F1016.1	SERIAL NO. 09/526,403
				APPLICANT Sanberg, et al.	
				FILING DATE 03/15/2000	GROUP 1617
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT					

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL	TRANSLATION	
							YES	NO
/	F1	EP 0 537 993 A1	21 April 1993	EP				

OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)

/	D1	Hayashi, E., et al., "Comparative studies on anti-nicotinic action of hexamethonium, mecamylamine and adenosine in the guinea pig isolated ileum," <i>Japan J. Pharmacol.</i> , 27: 659-665 (1997).
/	D2	Sanberg, P.R., et al., "Nicotine for the Treatment of Tourette's Syndrome," <i>Pharmacol. Ther.</i> , 74(1): 21-25 (1997).
/	D3	Suchocki, J.A., et al., "Synthesis of 2-exo-and 2-end-mecamylamine analogs. Structure-activity relationships for nicotinic antagonism in the central nervous system," <i>Journal of Medicinal Chemistry</i> , 34: 1003-1010 (1991).
/	D4	European Patent Application No. 98 93 9328.5, Supplementary European Search Report issued December 3, 2003.

EXAMINER		DATE CONSIDERED
		12/10/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O I P E DEC 05 2003 U.S. PATENT & TRADEMARK OFFICE JC59 759		FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DKT NO. T103 F1016.1	SERIAL NO. 09/526,403
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Paul R. Sanberg, et al.	
				FILING DATE 03/15/2000	GROUP
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)					
<p>D1 Ballivet, et al., "Nicotine Acetylcholine . . . elegans," JMB, 2296, pp. 261-269 (1996)</p> <p>D2 Banerjee, et al., "[³H]Mecamylamine Binding to Rat Brain Membranes," <i>Biochemical Pharmacology</i>, Vol. 40, No. 9, pp. 2105-2110 (1990)</p> <p>D3 Bianchi, C. and L. Tomasi, "Central nervous system and autonomic nervous system effects of amantadine and of some standard anti-Parkinson drugs," <i>Pharmacology</i>, 10(4), 226-237 (1973).</p> <p>D4 Bruun, R.D. and C.L. Budman, "Risperidone as a treatment for Tourette's syndrome," <i>J.Clin. Psychiatry</i>, 57(1): 29-31 (1996).</p> <p>D5 Emerich, et al., "Nicotine . . . Locomotor Hypoactivity," <i>Pharm. Biochem. & Behav.</i>, Vol. 38, pp. 875-880 (1991)</p> <p>D6 Emerich, et al., "Nicotine . . . of Haloperidol," <i>Psychopharm. Bulletin.</i>, Vol. 27(3): 385-390 (1991).</p> <p>D7 Erdmann, R., "Nicotine in neuropsychiatric movement disorders," <i>Fortschr Neurol Psychiatr.</i>, 64(9): 362-366 (1996).</p> <p>D8 Freund, R.K., et al., "Nicotine effects in mouse hippocampus are blocked by mecamylamine, but not other nicotinic antagonists," <i>Brain Res.</i>, 511(2): 187-191 (1990).</p> <p>D9 Ghaemi, S.N., et al., "Acute treatment of bipolar disorder with adjunctive risperidone in outpatients," <i>Can. J. Psychiatry</i>, 42(2): 196-199 (1997).</p> <p>D10 Green, M.F., et al., "Does Risperidone Improve Verbal Working Memory in Treatment-Resistant Schizophrenia?" <i>American Journal of Psychiatry</i>, 154(6): 799-804 (1997).</p> <p>D11 Hsu, W., "Toxicity and Drug Interactions of Levamisole," <i>HAVMA</i>, Vol. 176, No. 10, pp. 1166-1169 (May 1980)</p> <p>D12 Ivanová, S. and A. J. Greenshaw, "Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron," <i>Psychopharmacology</i>, 134(2): 187-192 (1997).</p> <p>D13 Jankovic, J. and H. Rohaidy, "Motor, behavior and pharmacologic findings in Tourette's Syndrome," <i>Can. J. Neurol. Sci.</i>, 14(3 Suppl.): 541-546 (1987).</p> <p>D14 Jolles, J., et al., "Cognitive Impairment in Elderly People," <i>Drugs & Aging</i>, 7(6): 459-479 (1995).</p> <p>D15 <i>The Lancet</i>, "Nicotine Gum & Haloperidol in Tourette's Syndrome," p. 592 (Mar. 12, 1998)</p> <p>D16 <i>The Lancet</i>, "Transdermal nicotine patch . . . in Tourette's Syndrome," Vol. 342, P. 182 (Jul. 17, 1993)</p> <p>D17 Levin, E. D. and D. Torry, "Acute and chronic nicotine effects on working memory in aged rats," <i>Psychopharmacology</i>, 123: 88-97 (1996).</p> <p>D18 Lindström, E., et al., "Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia," <i>Clin. Ther.</i> 17(3): 402-412 (1995).</p> <p>D19 Lombroso, P.J., et al., "Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report," <i>J. Am. Acad. Child Adolesc. Psychiatry</i>, 34(9): 1147-1152 (1995).</p> <p>D20 Lomboros, P.J., et al., "Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report," <i>J. Am. Acad. Child Adolesc. Psychiatry</i>, 35(3): 394 (1996).</p> <p>D21 McConville, et al., "The Effects . . . in Tourette's Disorder," <i>Biol. Psychiatry</i>, Vol. 31(8): 832-840 (1992)</p> <p>D22 McConville, et al., "Nicotine . . . in Tourette's Syndrome," <i>Amer. J. Psychiatry</i>, 148(6): 793-794 (Jun. 1991)</p> <p>D23 <i>Pharmacol Ther.</i>, "Nicotine for the Treatment of Tourette's Syndrome," Vol. 74, No. 1, pp. 21-25 (1997)</p> <p>D24 <i>Psychopharmacologia</i> (Berl.), "Nicotine-Like . . . after . . . Mecamylamine in . . . rats," 46, pp. 119-121 (1976)</p>					
EXAMINER		DATE CONSIDERED 12/10/00			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

O P E JCS 6 DEC 05 2003 PATENT & TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DKT NO. T103 F1016.1	SERIAL NO. 09/526,403
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Paul R. Sanberg, et al.	FILING DATE 03/15/2000	GROUP
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)				
	D25	Rupniak, et al. "Antinociceptive and Toxic Effect . . . Attributable to Nicotinic Agonist Activity," <i>Brit. J. Pharmacol.</i> , 113(4): 1487-1493 (1994)		
	D26	Sallee, F.R., et al., "Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder," <i>Acta Psychiatr. Scand.</i> , 90(1): 4-9 (1994).		
	D27	Sallee, F.R., et al., "Pharmacokinetics of pimozide in adults and children with Tourette's syndrome," <i>J. Clin. Pharmacol.</i> , 27(10): 776-781 (1987)		
	D28	Sallee, F.R., et al., "Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder," <i>Am. J. Psychiatry</i> , 154(8): 1057-1062 (1997).		
	D29	Sanberg, et al., "Nicotine as a Therapeutic Adjunct for Tourette's Syndrome," pp. 35-41 (1997)		
	D30	Sanberg, et al., "Nicotine . . . with Tourette's Syndrome," <i>Biomed & Pharmacother.</i> , 43, pp. 19-23 (1989)		
	D31	Sanberg, et al., "Nicotine . . . Striatal Mechanisms," <i>Pharmacol. Biochem & Behavior</i> , Vol. 46: 303-307 (1993)		
	D32	Sano Corporation website (1997)		
	D33	Sawada, S., et al., "Augmenting action of nicotine on population spikes in the dentate gyrus of the guinea pig," <i>Neurosci Res.</i> , 20(4): 317-322 (1994).		
	D34	Schonenberger, et al., "Preparation of Optically Active . . .," <i>Helvetica Chimica Acta</i> , Vol. 69, pp. 283-287 (1986).		
	D35	Seumaru, et al., "Characteristics of tail-tremor induced by nicotine in rats," <i>Naonyn-Schmiedeberg's Arch Pharmacol.</i> , 350:153-157 (1994).		
	D36	Shapiro, E., et al., "Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome," <i>Arch. Gen. Psychiatry</i> , 46(8): 722-730 (1989).		
	D37	Shieh, et al., "Sexual Differences in the Diurnal Changes . . . of Neuron Activity in Rat: Role of Cholinergic Control," <i>Biology of Reproduction</i> , Vol. 54, pp. 987-992 (1996)		
	D38	Shytle, et al., "Nicotine, Tobacco and Addiction," <i>Int'l Weekly Journal of Science</i> , Vol. 384, PP. 18-19 (1997)		
	D39	Shytle, et al., "Researchers Exploring . . . TS Treatment," <i>Tourette Syn. Assoc.</i> , 25(1): 1, 3, 7 (1997)		
	D40	Shytle, et al., "Transdermal Nicotine for Tourette's Syndrome," <i>Drug Development Research</i> , Vol. 38, pp. 290-298 (1996)		
	D41	Silver, et al., "Case Study . . . In Tourette's Syndrome," <i>J. Amer. Child & Adolesc. Psych.</i> , Vol. 35(12), pp. 1631-1636 (1996)		
	D42	Stone , et al., "Chemistry and Structure-Activity Relationship of Mecamylamine and Derivatives," <i>Journal of Medicine & Pharm. Chemistry</i> , Vol., 5(4), pp. 665-690 (1962)		
	D43	<i>The Merk Index</i> , "5654. Mecamylamine," p. 905 (1989)		
EXAMINER		DATE CONSIDERED 12/10/04		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				